手法を比較

	Montgomery-Åsberg Depression Rating Scale (MADRS)	迅速抑うつ症状評価尺度 (QIDS)
分野	臨床心理学	臨床心理学
系統	Process / pipeline	Process / pipeline
提唱年	1979	2003
提唱者	Stuart Montgomery & Marie Åsberg	A. John Rush
種類	Clinician-rated interview scale	Self-report or clinician-administered questionnaire
原典	Montgomery, S. A., & Åsberg, M. (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry, 134, 382–389.	Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., & Ninan, P. T. (2003). The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biological Psychiatry, 54(5), 573–583.
別名	MADRS, Montgomery-Asberg Depression Rating Scale	QIDS, Quick Inventory of Depressive Symptomatology-Self Report, QIDS-SR
関連	5	4
概要	The Montgomery-Åsberg Depression Rating Scale is a 10-item clinician-rated assessment designed by Stuart Montgomery and Marie Åsberg in 1979 to measure depression severity and track treatment response. Published in the British Journal of Psychiatry, the MADRS was developed as an alternative to longer instruments like the Hamilton Depression Rating Scale, emphasizing items most sensitive to treatment change. It has become a primary outcome measure in antidepressant trials and is widely used in both research and clinical practice across psychiatry, primary care, and medical specialty settings.	The Quick Inventory of Depressive Symptomatology is a 16-item assessment designed by A. John Rush and colleagues to efficiently measure the severity of depressive symptoms in adults. Published in Biological Psychiatry in 2003, the QIDS exists in both self-report (QIDS-SR) and clinician-rated (QIDS-C) versions. It was developed as a brief alternative to the longer Inventory of Depressive Symptomatology (IDS, 30 items) while maintaining comprehensive coverage of DSM-IV depressive symptoms. The QIDS has become a standard outcome measure in treatment research, particularly in large comparative effectiveness trials.